Longeveron (LGVN) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
August 11, 2023 7:30 AM EDTELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-BÂ in HLHS
Top Line Results for CLEAR MIND Alzheimers disease Phase 2a Trial Anticipated by October 2023
Company Strengthens Leadership Team and Board of Directors with Distinguished New Additions
Company to Hold Conference Call and Webcast Today, August 11, 2023 at 8am Eastern Time
MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative... More
